Considerable progress has occurred in the fields of oncology and hematologic malignancies during the 7 years since the third edition of the Atlas of Diagnostic Oncology was published. As a result, it was felt that a fourth edition of this teaching textbook was justified. All chapters from the previous edition have been updated, many with new co-authors, and several chapters have been extensively revised to include new knowledge and data in molecular biology, genetic studies, and staging procedures.
- Two new topics have been added, the first to Chapter 7: “Cancer of the Gastrointestinal Tract” (Neuroendocrine Tumors by Dr. Matthew Kulke) and the second to Chapter 12: “Sarcomas of Soft Tissue and Bone” (Gastrointestinal Stromal Tumor by Drs. Suzanne George, Jason Hornick, and George Demetri).
- With the rapid progress in technology, specialization, and staging studies in the field of radiology, the topic of nuclear medicine has been expanded into a new and separate chapter organized by Drs. Annick van den Abbeele and Steven Burrell.
- Likewise, a new chapter, titled “Malignant Mesothelioma,” has been developed by Drs. Pasi Jänne, David Wu, and Lucian Chirieac, experts in this challenging and aggressive disease now seen with increased frequency worldwide. Malignant mesothelioma was previously covered in the Lung Cancer chapter, after initial discussion in the Sarcoma chapter.
- One other new chapter has been added to this Atlas—Chapter 20, “Complications of Cancer,” by Dr. Nadine A. Jackson and myself—to complement Chapter 21, “Systemic and Mucocutaneous Reactions to Chemotherapy”.
Thus, the fourth edition of Atlas of Diagnostic Oncology has five new chapters and topics with a total of 24 new authors and coauthors, all with academic positions at Harvard Medical School and cancer experts at the Dana-Farber Cancer Institute, Massachusetts General Hospital, and the Brigham and Women's Hospital.
The chapter format has remained the same: a general review of the cancer including incidence, epidemiology, etiology, and histopathology with molecular biology when relevant, and clinical features, which is followed by diagnostic studies and current clinical and pathologic staging. Most of the chapters use staging nomenclature from the sixth edition (2002) of the American Joint Committee on Cancer (AJCC). The seventh edition of the AJCC staging system will be published in late 2009. A new TNM staging system has been developed by the International Association for the Study of Lung Cancer (IASLC) in collaboration with the International Union Against Cancer (IUAC) and the AJCC and is included in Chapter 5. Detailed charts are used for histopathologic classification, diagnostic studies, and prognostic factors when important. Generous illustrations with detailed figure legends are utilized for examples of histopathology, staging, radiographs, CT, MRI, and PET images and differential diagnosis, along with examples of various clinical manifestations and relevant up-to-date references. As with previous editions, detailed treatment recommendations are not included since these are outside the goals of this book. The reader is referred to standard oncology textbooks and current review articles for details concerning management of cancer and hematologic malignancy patients.
Of note, previous editions of this Atlas had 35-mm slide sets included for teaching purposes. With advances in computer technology it was possible to provide a CD-ROM with the second and third editions. With the fourth edition, a website will be available to download images of choice. These images have proven to be of great value for teaching medical and nursing students, house staff, and fellows. These images will also increase the scope of this Atlas by allowing for use in tumor boards, lectures, and other teaching applications. This fulfills our original goals of preparing a unique and illustrative educational Atlas of Diagnostic Oncology.
Arthur T. Skarin, MD
Foreword
As the field of clinical oncology moves forward, so must the published reference literature. The rate of new knowledge has accelerated and resulted in new diagnostic and therapeutic modalities. Understanding the unique biology of tumors that were previously included in major disease groups has resulted in their separation as distinct entities in the Atlas of Diagnostic Oncology –entities such as mesothelioma, gastrointestinal stromal tumors, and neuroendocrine gastrointestinal neoplasms. The updates, graphics, and comprehensive summaries have made this a classic in the past and assure its status in the near future. Nuclear radiology is an emerging field that has brought imaging into a new era. Imaging technology has improved the accuracy of staging and the evaluation of response. There is a new section that has brought this field forward and up to date.Dr. Arthur Skarin brings to this volume his commitment to visual and graphic aspects of medical oncology. He is a talented photographer and outstanding medical oncologist. He brings these talents together as editor of the Atlas of Diagnostic Oncology. In recognition of his talents, he has been a long-serving editor of “Images in Oncology” in the Journal of Clinical Oncology. I am particularly proud to write this foreword as 16 of the 21 chapters have authors who trained at the Dana-Farber Cancer Institute. This edition includes writers who are now on staffs of the Massachusetts General Hospital and Brigham and Women's Hospital. This edition will offer the clinician a ready reference to all the important issues in the daily practice of clinical oncology. The clinician will also be able to use the accompanying ExpertConsult web site to download teaching illustrations. This is indeed a multidisciplinary text with contributors from the related areas of surgery, pathology, radiology, and dermatology. The Atlas of Diagnostic Oncology continues an important tradition in the oncologic literature. It is renowned for its unique combination of talents. The fourth edition enhances this reputation further. I am very proud of my professional relationships with the editors and contributors. The honor is mine to write this foreword.
Senior Physician, Dana-Farber Cancer Institute
Key Features
- A superb collection of more than 2,500 images encompasses the full spectrum of pathologic and radiologic studies, staging, and clinical manifestations, highlighting the pathologic anatomy of common clinical entities.
- A consistent chapter organization covers each disease’s incidence, epidemiology, etiology, and histopathology - as well as molecular biology, clinical features, diagnostic studies, and current clinical and pathologic staging - providing all the assistance you need to evaluate and monitor your patients effectively.
- This unique pictorial resource is a superb complement to treatment handbooks and major oncological texts.
Website Features
- Consult the book from any computer at home, in your office, or at any practice location.
- Instantly locate the answers to your clinical questions via a simple search query.
- Quickly find out more about any bibliographical citation by linking to its MEDLINE abstract.
- Images: Browse a Library of all book images. Easily select, organize, and download your images into a presentation.
New to This Edition
- Expert Consult functionality provides online access to the complete text, fully searchable, with illustrations downloadable for your personal presentations, and case studies keyed to the book, at expertconsult.com.
- Completely updated chapters covering the newest genetic markers, imaging modalities, and pathologic techniques enable you to get the best results from today’s diagnostic tools.
- An expanded chapter on evaluating the side effects of chemotherapy, with additional images of reactions to the newest regimens, alerts you to potential common and uncommon side effects.
- Two new chapters address the complications of cancer and modern use of diagnostic PET scans, keeping you up to date on these hotly debated topics in the oncology community.
- A third new chapter covers malignant mesothelioma of the lung, plus other sites.
Contents
- Introduction
- Chapter 1 - The Role of Molecular Probes and Other Markers in the Diagnosis of Malignancy
- Chapter 2 - Radiographic Evaluation of Cancer
- Chapter 3 - Nuclear Medicine in Oncology
- Chapter 4 - Cancer of the Head and Neck region
- Chapter 5 - Lung Cancer and Tumors of the Heart and Mediastinum
- Chapter 6 - Malignant Mesothelioma
- Chapter 7 - Cancer of the Gastrointestinal Tract and Neuroendocrine Tumors
- Chapter 8 - Cancer of the Genitourinary Tract
- Chapter 9 - Gynecologic Tumors and Malignancies
- Chapter 10 - Breast Cancer
- Chapter 11 - Endocrine Neoplasia
- Chapter 12 - Sarcomas of Soft Tissue and Bone and Gastrointestinal Stromal Tumors
- Chapter 13 - Skin Cancer
- Chapter 14 - Neoplasms of the Central Nervous System
- Chapter 15 - Acute and Chronic Leukemias
- Chapter 16 - Hodgkin Disease and Non-Hodgkin Lymphomas
- Chapter 17 - Multiple Myeloma and Plasma Cell Dyscrasias
- Chapter 18 - Solid Tumors in Childhood
- Chapter 19 - AIDS-Associated Malignancies
- Chapter 20 - Complications of Cancer
- Chapter 21 - Systemic and Mucocutaneous Reactions to Chemotherapy
About the Author
Arthur T. Skarin, MD, FACP, FCCP, earned his MD from the State University of New York at Buffalo in 1961, and received postgraduate training in internal medicine at the Millard Fillmore Teaching Hospital in Buffalo. After a fellowship in hematology and oncology at Boston City Hospital, he joined Brigham and Women's Hospital and Dana-Farber Cancer Institute (DFCI) in 1970. He served as Clinical Director of the DFCI Hematology Laboratory as well as Chairman of the Laboratory Committee from 1970 to 1998. He established the multimodality thoracic oncology clinic in 1975 and has served as Medical Director since then. During that time he also was chair of the human protection committee (IRB) for 12 years and became Associate Professor of Medicine at Harvard Medical School. He has been the Principal Investigator (PI) as well as site PI on numerous clinical research Phase I, II and III trials, both at DFCI Partners Cancer Care and the Cancer and Leukemia Group B (CALGB). He was appointed a Research Subject Advocate (RSA) in 2002 for NIH funded studies at the Brigham and Women's Hospital General Clinical Research Center (GCRC) and DFCI. Dr. Skarin is a board member of the American Journal of Oncology Review, the Journal of Cinical Oncology, Hospital Physician and also president of the Massachusetts Society of Clinical Oncologists.
He has published 150 original articles, 97 abstracts, 67 chapters in books and 4 books.
Product Details
- Hardcover: 654 pages
- Publisher: Mosby; 4 edition (December 23, 2009)
- Language: English
- ISBN-10: 0323059058
- ISBN-13: 978-0323059053
- Product Dimensions: 12.2 x 9.2 x 1.3 inches
List Price: $250.00